The enclomiphene doses on record come straight from its trials: the Phase 3 program dosed 12.5 mg and 25 mg once daily by mouth (Kim et al., 2016), and the earlier pharmacodynamic study compared those same two strengths and characterized a plasma half-life near 10 hours — the reason every trial dosed it once per day (Wiehle et al., 2013). This guide reports those figures as documented data points, not as instructions.
Research-context information only. Enclomiphene is an investigational drug not approved by the FDA. Protocols, doses, and reactions reported below come from published clinical trials and self-reported community sources. This article reports what has been documented, not what should be done. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. Consult a licensed physician for personal medical decisions.
Enclomiphene is an oral selective estrogen receptor modulator (SERM) — the trans-isomer of clomiphene citrate — studied as a fertility-sparing route to raising the body's own testosterone. Below is what the trials documented on the dose, half-life, timing, study duration, and the bloodwork researchers tracked.
Quick Reference: Trial-Documented Dosing
| Parameter | What the trials documented |
|---|---|
| Trial dose | 12.5 mg and 25 mg once daily (Kim 2016) |
| Route | Oral capsule (small molecule, no injection) |
| Timing | Once daily; morning dosing used in trial protocols |
| Frequency | Once per day |
| Half-life | ~10 hours plasma (Wiehle 2013) — the once-daily rationale |
| Study duration | ~12-24 weeks (defined trial windows) |
| Market format | 12.5 mg capsules most common; some 25 mg |
| Reconstitution | None — shelf-stable oral capsule |
| Regulatory status | Completed Phase 3; never FDA-approved |
These values report what published trials used and measured. They are not a dosing recommendation.
12.5 mg vs 25 mg: What Trials Used and What the Market Sells
Both strengths appear across the clinical record. The pharmacodynamic study (Wiehle et al., 2013) directly compared 12.5 mg and 25 mg once-daily oral enclomiphene and documented a dose-related response — both raised total testosterone, LH, and FSH, with 25 mg producing somewhat larger hormone increases than 12.5 mg. The Phase 3 studies (Kim et al., 2016) carried both doses forward, and mean total testosterone rose from a baseline near 205 ng/dL into roughly the 410-450 ng/dL range across the arms.
On the research-chemical market, 12.5 mg per capsule is the most common format — the strength carried through the trial program — with some vendors also listing 25 mg. The reported difference between the two is a trial data point, not a titration instruction: the studies documented what each strength did, they did not tell readers which to take. For how capsules are priced and what a certificate of analysis must confirm, see the enclomiphene buying guide.
Half-Life and Once-Daily Timing
Enclomiphene's dosing cadence follows from its pharmacokinetics. Because it is the trans-isomer of clomiphene, it clears the body far faster than the longer-lasting, more estrogenic zuclomiphene fraction that accumulates on racemic clomiphene. Wiehle and colleagues (2013) characterized enclomiphene as orally active with a plasma half-life in the region of 10 hours, and that short half-life is the pharmacological rationale the trials cited for once-daily administration rather than the every-few-days schedule sometimes used with clomiphene.
Trial protocols administered the daily dose in the morning. Every controlled study in the program used the once-daily oral route, so the once-a-day cadence is the single most consistent feature of the documented dosing.
Study Durations: The 12-24 Week Window
The controlled studies ran for defined windows, not open-ended cycles. The Kaminetsky (2013) proof-of-principle study reported outcomes at three and six months, and the Phase 3 studies (Kim et al., 2016) dosed daily across a multi-week treatment period, with reported study durations clustering in the 12-24 week range. A randomized Phase 2 trial (Wiehle et al., 2014) followed the same daily-dosing structure over its treatment window.
Reported this way, the duration is a trial fact — how long the studies ran — not a recommended "cycle." The research record does not define an on/off cycling schedule for enclomiphene the way community protocols do for injectable peptides.
What Bloodwork the Trials Tracked
Across the program, researchers measured a consistent panel to characterize the compound's effect:
- Total testosterone — the primary endpoint; rose from ~205 ng/dL baseline into the ~410-450 ng/dL range on daily dosing (Kim 2016).
- Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) — the upstream gonadotropins; both rose, confirming the effect came from a reawakened pituitary signal (Wiehle 2013).
- Estradiol — tracked because enclomiphene blocks estrogen feedback at the hypothalamus and pituitary.
- Semen parameters / sperm concentration — the defining measured result was preservation of sperm counts that topical testosterone reduced (Kaminetsky 2013, Kim 2016).
This describes what the studies measured to document the compound's action — it is not a monitoring protocol for personal use.
Ready to buy? Compare verified vendors on our best Enclomiphene sources page, or browse all coupon codes for up to 50% off.
